The global cancer drug giant ranks TOP10

，，，TOP10。

NO.

However, in the field of cell and gene therapy, Novartis’s world’s first approved CAR-T product, Kymriah, achieved a performance of US$474 million in 2020, an increase of 68% year-on-year.
At present, 27 countries around the world have approved at least one indication of Kymriah.
At the same time, Novartis has established 290 CAR-T treatment centers around the world, and it will accumulate its oncology business in the future.

In addition, among the newly launched products in 2020, camatinib for the treatment of non-small cell lung cancer and Asciminib for the treatment of leukemia will be Novartis’s new additions.

NO.
5 Johnson & Johnson

Johnson & Johnson’s total annual revenue in 2020 reached 45.
572 billion U.
S.
dollars, an increase of 8%, of which tumor business revenue reached 12.
367 billion U.
S.
dollars, accounting for 27.
1.
8% of total revenue, an increase of 15.
7% year-on-year.

The CD38 monoclonal antibody drug daratumomab and the BTK inhibitor ibrutinib are Johnson & Johnson's two major oncology products, which together contribute more than 8 billion U.
S.
dollars in revenue to Johnson & Johnson, accounting for 65% of the oncology business revenue.

The blockbuster drug daratumomab for multiple myeloma achieved sales of US$4.
19 billion in 2020, a year-on-year increase of 39.
8%, making it the drug with the highest sales in Johnson & Johnson's tumor pipeline.
At present, the indications of daratumumab cover the first to fourth line of multiple myeloma, and it has become the cornerstone of clinical therapy.
Ibritinib will achieve operating income of US$4.
128 billion in 2020, an increase of 21%.
After ibrutinib was launched in the United States in 2013, it quickly grew into one of Johnson & Johnson's fastest-growing anti-tumor drugs.
In addition, abiraterone, bortezomib, apatamide, etc.
also contributed to a certain degree.

NO.
6 AstraZeneca

AstraZeneca’s total annual revenue in 2020 reached US$26.
617 billion, an increase of 9%, of which revenue from the oncology business reached US$11.
455 billion, accounting for 43% of the total revenue, an increase of 23% year-on-year.

AstraZeneca’s tumor pipeline business has become an important component of its segment.
The star drugs osimertinib, olaparib, duvalizumab, dapagliflozin, etc.
, have brought a total of 10.
1 billion U.
S.
dollars in sales revenue.
Hittinib made a huge contribution, with total revenue of US$4.
3 billion, an increase of 36%.
In addition, the BTK inhibitor acatinib, the blockbuster HER2 ADC drug Enhertu (DS-8201) acquired from Daiichi Sankyo, and the first new drug for pediatric fibroids , simetinib , will all achieve high volumes in 2020.

It is worth mentioning that in December 2020, osimertinib was included in the latest version of China's medical insurance catalogue for the first-line treatment of EGFR mutation-positive advanced or metastatic non-small cell lung cancer ( NSCLC ).
AstraZeneca disclosed in its financial report that, based on the inclusion of osimertinib in the latest version of the medical insurance catalog, and its second-line treatment of NSCLC has also received medical insurance renewal, osimertinib is expected to be further increased in China.

NO.
7 Pfizer

Pfizer’s total annual revenue in 2020 reached US$41.
908 billion, an increase of 2%, of which revenue from the oncology business reached US$10.
867 billion, accounting for 25.
9% of the total revenue, an increase of 21% year-on-year.

Among Pfizer's oncology products, the breast cancer drug piperacillil scored 53.
92 revenue and contributed nearly half of Pfizer’s oncology revenue.
As the world’s first CDK4/6 inhibitor approved for marketing, piperacillil has already Become the first-line therapy for HR+/HER2- breast cancer patients.
However, from the perspective of revenue growth, piperacillil has dropped from 20% in 2019 to 9%, while its competitor, Eli Lilly’s new breast cancer drug, abecilil, has increased by 57% in 2020.
Seely's status is not unassumingly shaken, but pipercillide is currently actively developing new indications.

Another bright tumor product of Pfizer is the non-small cell lung cancer drug loratinib.
Although its revenue in 2020 is only US$204 million, the increase will reach 78%, the highest growth among all products, and it is also among Pfizer's newly-listed drugs in the past two years.
The best performing one.

In addition, there is the kidney cancer drug axitinib, which has revenue of nearly 800 million US dollars, an increase of 65%; the prostate cancer drug enzalutamide brings about 1 billion US dollars in revenue, an increase of 22%; rituximab and bevacizumab The monoclonal antibodies brought a total of 310 million US dollars in revenue.

NO.
8 Amgen

Amgen’s total annual revenue in 2020 reached US$25.
424 billion, an increase of 9%, of which revenue from the oncology business reached US$8.
037 billion, accounting for 31.
6% of the total revenue, an increase of 2% year-on-year.

The two highest-income products in Amgen's oncology field are desulumab and carfilzomib, which together contributed nearly US$3 billion in revenue.
In addition, biosimilar drugs bevacizumab and trastuzumab contributed nearly 14 Billion dollars in revenue.

In addition, Amgen’s targeted anti-cancer drug sotorasib was granted breakthrough drug designation by the FDA in December 2020 for the treatment of KRAS G12C mutant lung cancer.
Currently, the drug has been submitted in the United States, Europe, Canada, the United Kingdom, Brazil, and Australia.
The listing application may be the first small molecule targeted inhibitor of KRAS approved for marketing .

NO.
9 AbbVie

AbbVie’s total annual revenue in 2020 reached US$45.
804 billion, an increase of 37%, of which revenue from the oncology business reached US$6.
651 billion, accounting for 14.
5% of the total revenue, an increase of 21.
7% year-on-year.

AbbVie's income pillar mainly comes from the king of medicine Humira, and a single medicine contributes US$19.
832 billion.
In the field of oncology, AbbVie does not have many products, but the core products Ibritinib and Venecla are first in class.

As the first listed BTK inhibitor, AbbVie’s Ibritinib reached revenue of US$5.
314 billion in 2020, and sales increased by 13.
7%, becoming an important support for its oncology business.
In 2015, AbbVie’s revenue was 21 billion US dollars.
The U.
S.
dollar obtained the US market equity of Ibritinib from Johnson & Johnson.
Johnson & Johnson's Ibritinib will achieve operating income of US$4.
128 billion in 2020, an increase of 21%.

Venecla achieved revenues of US$1.
337 billion in 2020, an increase of nearly 70%.
As the world’s first listed Bcl2 inhibitor, its importance in various anti-cancer combination therapies is gradually being recognized.
At present, Venecla is in progress.
Has more than 80 clinical trials.
According to the results of its first-line trials, Venacella may become the first-line drug for the treatment of CLL in the next few years.

NO.
10 Eli Lilly

Eli Lilly’s total annual revenue in 2020 reached US$24.
54 billion, an increase of 10%, of which oncology business revenue reached US$5.
158 billion, accounting for 21% of total revenue, an increase of 22% year-on-year.

Eli Lilly’s oncology business pipeline has contributed the most to the old drug pemetrexed for lung cancer and pleural mesothelioma.
It has been 17 years since it was approved in 2004.
Its 2020 revenue was 2.
33 billion U.
S.
dollars, an increase of 10%.
Nearly half of Eli Lilly Oncology's performance is revenue.

Eli Lilly’s other major oncology product is the breast cancer drug Abexili, which has an increase of 57% in 2020, the largest increase among all products, contributing approximately US$900 million in revenue.
Abbesili is the third CDK4/6 inhibitor to be marketed in the world.
Although Pfizer’s piperacillil’s revenue in 2020 (US$5.
392 billion) far surpasses that of abesili, the market has been shaken by the latter, with obvious Decline.

In addition to the above two, ramucirumumab, sintilimab cooperating with Innovent, and the world's first RET kinase inhibitor Retevmo acquired from LOXO Oncology also contributed.
In addition, its BTK C481S inhibitor LOXO-305 has also entered phase III clinical trials and will be on the market soon.